ArticleClinical and translational gastroenterology2020
Low Pepsinogen I/II Ratio and High Gastrin-17 Levels Typify Chronic Atrophic Autoimmune Gastritis Patients With Gastric Neuroendocrine Tumors.
Article in Clinical and translational gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review.Gastroenterology · 2021Guideline
- Serum pepsinogen Ⅰ and the pepsinogen Ⅰ/Ⅱ ratio as a non-invasive predictive marker for autoimmune metaplastic atrophic gastritis.Journal of translational autoimmunity · 2026Article
- Distinguishing second primary tumors from local recurrence in type 1 gastric neuroendocrine tumors: a risk-stratified management strategy.Surgical endoscopy · 2026Article
- Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort.Frontiers in endocrinology · 2026Article
- Response to Dell'Unto et al.The American journal of gastroenterology · 2025Article
- Risk assessment of type I gastric neuroendocrine tumors based on endoscopic and clinical features of autoimmune gastritis.World journal of gastroenterology · 2025Article
- A Prospective Study on the Detection of Gastric Neoplasms Using Pepsinogen and Gastrin-17 Levels.Gut and liver · 2025Observational
- Monitoring the follow-up of autoimmune chronic atrophic gastritis using parietal cell antibodies and markers of gastric function.Journal of translational autoimmunity · 2025Review
- Autoimmune Gastritis: Unveiling the Mystery.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Autoimmune Gastritis in Korean Patients with Gastric Tumors: Clinicopathologic Correlations and Diagnostic Histological Features.Gut and liver · 2025Article
- Association between autoimmune gastritis and gastric polyps: Clinical characteristics and risk factors.World journal of gastrointestinal oncology · 2025Article
- Update understanding on diagnosis and histopathological examination of atrophic gastritis: A review.World journal of gastrointestinal oncology · 2024Review
- Autoimmune Gastritis and Hypochlorhydria: Known Concepts from a New Perspective.International journal of molecular sciences · 2024Review
- Piezo channels in the intestinal tract.Frontiers in physiology · 2024Review
- Machine learning identifies a 5-serum cytokine panel for the early detection of chronic atrophy gastritis patients.Cancer biomarkers : section A of Disease markers · 2024Article
- Autoimmune gastritis diagnosed due to recurrent gastric neuroendocrine tumor: a case report.Frontiers in medicine · 2024Article
- Elucidation of the mechanism of berberine against gastric mucosa injury in a rat model with chronic atrophic gastritis based on a combined strategy of multi-omics and molecular biology.Frontiers in pharmacology · 2024Article
- Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study.BMC gastroenterology · 2023Article
- Clinical value of serum pepsinogen in the diagnosis and treatment of gastric diseases.World journal of gastrointestinal oncology · 2023Review
- Update in Molecular Aspects and Diagnosis of Autoimmune Gastritis.Current issues in molecular biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic atrophic autoimmune gastritis (CAAG) can lead to the development of gastric neuroendocrine tumors (gNETs) and can be accompanied by other autoimmune diseases. This study aimed to determine, in CAAG patients, the association of gNET development, the prevalence of autoimmune diseases other than CAAG, the association of autoimmunity, and gNET development with pepsinogen I, II, gastrin-17, and Helicobacter pylori infection analysis.
methodsWe determined the prevalence of gNETs and other autoimmune diseases and analyzed pepsinogen I and II, gastrin-17 serum levels, and H. pylori infection in all patients diagnosed with CAAG at our hospital between 2013 and 2017.
resultsA total of 156 patients were studied and in 15.4% was observed concomitant gNET. Approximately 68.6% had at least 1 other autoimmune disease at diagnosis of CAAG. Approximately 60.9% had autoimmune thyroiditis, followed by diabetes (19.9%) and autoimmune polyendocrine syndrome (12.8%). CAAG patients with and without gNET had similar rates of comorbidity with other autoimmune diseases, but the pepsinogen I/II ratio was lower in patients with gNET (1.6 vs 4.5, P = 0.018). Receiver operating characteristic curve analyses identified a pepsinogen I/II ratio <2.3 and gastrin-17 levels >29.6 pmol/L as cutoffs distinguishing CAAG patients with gNET from those without. The combined use of these cutoff correctly identified 16 of the 18 CAAG patients with gNET (P = 0.007). H. pylori infection was observed in 28.7% of cases tested but did not associate with gNET. DISCUSSION: This study suggests that a low pepsinogen I/II ratio and high gastrin-17 levels characterize patients with CAAG and gNET and confirms the frequent coexistence of CAAG with other autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.